Home/Pipeline/Inreda AP®

Inreda AP®

Type 1 Diabetes

CommercialActive

Key Facts

Indication

Type 1 Diabetes

Phase

Commercial

Status

Active

Company

Inreda Diabetic

About Inreda Diabetic

Inreda Diabetic is a pioneering private company in the metabolic device sector, focused on a fully closed-loop artificial pancreas system. Its core technology, the Inreda AP®, differentiates itself by using a dual-hormone (insulin and glucagon) approach to automate blood glucose management. The company has progressed to a commercial stage in the Netherlands, with over 100 users, and recently published significant long-term clinical data in The Lancet Digital Health. Inreda represents a advanced, though niche, contender in the growing automated insulin delivery market.

View full company profile

Therapeutic Areas

Metabolic Disease Type 1 Diabetes

Other Type 1 Diabetes Drugs

Drug	Company	Phase	Status
eRapa	Biodexa Pharmaceuticals	Preclinical	Research
ImmCelz™	Creative Medical Technology Holdings	Clinical Trial	Active
Adimune (ADi-001/002)	Aditxt	Preclinical / Early Clinical	Active
MSC‑Diabetes	Advancells	Phase 1	Active
BioChaperone® Lispro (THDB0206)	Adocia	Phase 3	Active
AdoShell® Islet Cell Therapy	Adocia	Preclinical	Platform Development
Pediatric Indications (<2 years)	Tandem Diabetes	Research	Exploratory
Icovamenib (BMF-219)	Biomea Fusion	Phase 2	Completed Follow-up, Data Pending
Undisclosed Novel Strategy	CG Scientific	Pre-clinical	Early Research
Sotagliflozin	Lexicon Pharmaceuticals	Phase 3	Regulatory Path Uncertain
Stem Cell-Derived Beta Cells	BioTalentum	Pre-clinical	Active
NICHE	Continuity Biosciences	Pre-clinical	Active